{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T18:17:39Z","timestamp":1791137859108,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,3,27]],"date-time":"2014-03-27T00:00:00Z","timestamp":1395878400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Toxicol"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1007\/s00204-014-1226-6","type":"journal-article","created":{"date-parts":[[2014,3,26]],"date-time":"2014-03-26T05:38:51Z","timestamp":1395812331000},"page":"121-136","source":"Crossref","is-referenced-by-count":42,"title":["Bone marrow microenvironment confers imatinib resistance to chronic myelogenous leukemia and oroxylin A reverses the resistance by suppressing Stat3 pathway"],"prefix":"10.1007","volume":"89","author":[{"given":"X.","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q.","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,3,27]]},"reference":[{"issue":"10","key":"1226_CR1","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1158\/1535-7163.MCT-08-0314","volume":"7","author":"NN Bewry","year":"2008","unstructured":"Bewry NN, Nair RR, Emmons MF, Boulware D, Pinilla-Ibarz J, Hazlehurst LA (2008) Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance. Mol Cancer Ther 7(10):3169\u20133175. doi: 10.1158\/1535-7163.MCT-08-0314","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"1226_CR2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/leu.2010.238","volume":"25","author":"D Bixby","year":"2011","unstructured":"Bixby D, Talpaz M (2011) Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia. Leukemia 25(1):7\u201322. doi: 10.1038\/leu.2010.238","journal-title":"Leukemia"},{"issue":"2","key":"1226_CR3","doi-asserted-by":"crossref","first-page":"e23828","DOI":"10.4161\/jkst.23828","volume":"2","author":"E Bournazou","year":"2013","unstructured":"Bournazou E, Bromberg J (2013) Targeting the tumor microenvironment: JAK-STAT3 signaling. Jak-Stat 2(2):e23828. doi: 10.4161\/jkst.23828","journal-title":"Jak-Stat"},{"key":"1226_CR4","doi-asserted-by":"crossref","first-page":"219241","DOI":"10.1155\/2008\/219241","volume":"2008","author":"V Caldera","year":"2008","unstructured":"Caldera V, Mellai M, Annovazzi L, Valente G, Tessitore L, Schiffer D (2008) Stat3 expression and its correlation with proliferation and apoptosis\/autophagy in gliomas. J Oncol 2008:219241. doi: 10.1155\/2008\/219241","journal-title":"J Oncol"},{"issue":"2","key":"1226_CR5","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2141.2006.06161.x","volume":"134","author":"P Coppo","year":"2006","unstructured":"Coppo P, Flamant S, De Mas V et al (2006) BCR-ABL activates STAT3 via JAK and MEK pathways in human cells. Br J Haematol 134(2):171\u2013179. doi: 10.1111\/j.1365-2141.2006.06161.x","journal-title":"Br J Haematol"},{"issue":"5","key":"1226_CR6","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.clml.2013.03.020","volume":"13","author":"JE Cortes","year":"2013","unstructured":"Cortes JE, Nicolini FE, Wetzler M et al (2013) Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib. Clin Lymphoma Myeloma Leuk 13(5):584\u2013591. doi: 10.1016\/j.clml.2013.03.020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"1226_CR7","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1101\/gr.GR-1649R","volume":"11","author":"M Dean","year":"2001","unstructured":"Dean M, Rzhetsky A, Allikmets R (2001) The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 11(7):1156\u20131166. doi: 10.1101\/gr.184901","journal-title":"Genome Res"},{"issue":"1","key":"1226_CR8","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.cancergencyto.2005.01.015","volume":"162","author":"S Galimberti","year":"2005","unstructured":"Galimberti S, Cervetti G, Guerrini F et al (2005) Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during Imatinib treatment. Cancer Genet Cytogenet 162(1):57\u201362. doi: 10.1016\/j.cancergencyto.2005.01.015","journal-title":"Cancer Genet Cytogenet"},{"issue":"5","key":"1226_CR9","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00432-009-0705-2","volume":"136","author":"Y Gao","year":"2010","unstructured":"Gao Y, Lu N, Ling Y et al (2010) Oroxylin A inhibits angiogenesis through blocking vascular endothelial growth factor-induced KDR\/Flk-1 phosphorylation. J Cancer Res Clin Oncol 136(5):667\u2013675. doi: 10.1007\/s00432-009-0705-2","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"1226_CR10","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/S0301-472X(01)00612-9","volume":"29","author":"SM Garrido","year":"2001","unstructured":"Garrido SM, Appelbaum FR, Willman CL, Banker DE (2001) Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5). Exp Hematol 29(4):448\u2013457","journal-title":"Exp Hematol"},{"issue":"8","key":"1226_CR11","doi-asserted-by":"crossref","first-page":"16348","DOI":"10.3390\/ijms140816348","volume":"14","author":"S Glowacki","year":"2013","unstructured":"Glowacki S, Synowiec E, Blasiak J (2013) The role of mitochondrial DNA damage and repair in the resistance of BCR\/ABL-expressing cells to tyrosine kinase inhibitors. Int J Mol Sci 14(8):16348\u201316364. doi: 10.3390\/ijms140816348","journal-title":"Int J Mol Sci"},{"issue":"10","key":"1226_CR12","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/nm1483","volume":"12","author":"L Jin","year":"2006","unstructured":"Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE (2006) Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 12(10):1167\u20131174. doi: 10.1038\/nm1483","journal-title":"Nat Med"},{"issue":"1\u20132","key":"1226_CR13","first-page":"107","volume":"1074","author":"HB Li","year":"2005","unstructured":"Li HB, Chen F (2005) Isolation and purification of baicalein, wogonin and oroxylin A from the medicinal plant Scutellaria baicalensis by high-speed counter-current chromatography. J Chromatogr A 1074(1\u20132):107\u2013110","journal-title":"J Chromatogr A"},{"key":"1226_CR14","unstructured":"Litzow MR (2006) Imatinib resistance: obstacles and opportunities. Arch Pathol Lab Med 130(5):669\u2013679. doi: 10.1043\/1543-2165(2006)130[669:IROAO]2.0.CO;2"},{"issue":"4","key":"1226_CR15","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.tiv.2007.01.015","volume":"21","author":"Y Liu","year":"2007","unstructured":"Liu Y, Zhang SP, Cai YQ (2007) Cytoprotective effects of selenium on cadmium-induced LLC-PK1 cells apoptosis by activating JNK pathway. Toxicol In Vitro Int J Publ Assoc BIBRA 21(4):677\u2013684. doi: 10.1016\/j.tiv.2007.01.015","journal-title":"Toxicol In Vitro Int J Publ Assoc BIBRA"},{"issue":"23","key":"1226_CR16","doi-asserted-by":"crossref","first-page":"9809","DOI":"10.1158\/0008-5472.CAN-08-1008","volume":"68","author":"FX Mahon","year":"2008","unstructured":"Mahon FX, Hayette S, Lagarde V et al (2008) Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res 68(23):9809\u20139816. doi: 10.1158\/0008-5472.Can-08-1008","journal-title":"Cancer Res"},{"key":"1226_CR17","doi-asserted-by":"crossref","first-page":"157496","DOI":"10.1155\/2012\/157496","volume":"2012","author":"S Manier","year":"2012","unstructured":"Manier S, Sacco A, Leleu X, Ghobrial IM, Roccaro AM (2012) Bone marrow microenvironment in multiple myeloma progression. J Biomed Biotechnol 2012:157496. doi: 10.1155\/2012\/157496","journal-title":"J Biomed Biotechnol"},{"key":"1226_CR18","doi-asserted-by":"crossref","unstructured":"Melo JV, Chuah C (2008) Novel agents in CML therapy: tyrosine kinase inhibitors and beyond. hematology\/the education program of the American Society of Hematology American Society of Hematology Education Program. 427\u2013435. doi: 10.1182\/asheducation-2008.1.427","DOI":"10.1182\/asheducation-2008.1.427"},{"issue":"6","key":"1226_CR19","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.leukres.2011.12.002","volume":"36","author":"RR Nair","year":"2012","unstructured":"Nair RR, Tolentino JH, Argilagos RF, Zhang L, Pinilla-Ibarz J, Hazlehurst LA (2012a) Potentiation of Nilotinib-mediated cell death in the context of the bone marrow microenvironment requires a promiscuous JAK inhibitor in CML. Leuk Res 36(6):756\u2013763. doi: 10.1016\/j.leukres.2011.12.002","journal-title":"Leuk Res"},{"key":"1226_CR20","first-page":"30","volume":"2","author":"RR Nair","year":"2012","unstructured":"Nair RR, Tolentino JH, Hazlehurst LA (2012b) Role of STAT3 in transformation and drug resistance in CML. Front Oncol 2:30. doi: 10.3389\/fonc.2012.00030","journal-title":"Front Oncol"},{"issue":"1","key":"1226_CR21","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1349-7006.2009.01365.x","volume":"101","author":"T Nambu","year":"2010","unstructured":"Nambu T, Araki N, Nakagawa A et al (2010) Contribution of BCR-ABL-independent activation of ERK1\/2 to acquired imatinib resistance in K562 chronic myeloid leukemia cells. Cancer Sci 101(1):137\u2013142. doi: 10.1111\/j.1349-7006.2009.01365.x","journal-title":"Cancer Sci"},{"issue":"4","key":"1226_CR22","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1182\/blood.V85.4.997.bloodjournal854997","volume":"85","author":"BA Roecklein","year":"1995","unstructured":"Roecklein BA, Torok-Storb B (1995) Functionally distinct human marrow stromal cell lines immortalized by transduction with the human papilloma virus E6\/E7 genes. Blood 85(4):997\u20131005","journal-title":"Blood"},{"issue":"3","key":"1226_CR23","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/leu.2010.287","volume":"25","author":"A Samanta","year":"2011","unstructured":"Samanta A, Perazzona B, Chakraborty S et al (2011) Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia. Leukemia 25(3):463\u2013472. doi: 10.1038\/leu.2010.287","journal-title":"Leukemia"},{"issue":"5","key":"1226_CR24","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/S1734-1140(12)70915-5","volume":"64","author":"X Song","year":"2012","unstructured":"Song X, Chen Y, Sun Y et al (2012) Oroxylin A, a classical natural product, shows a novel inhibitory effect on angiogenesis induced by lipopolysaccharide. Pharmacol Rep PR 64(5):1189\u20131199","journal-title":"Pharmacol Rep PR"},{"key":"1226_CR25","author":"KL Sweet","year":"2013","unstructured":"Sweet KL, Hazlehurst LA, Pinilla-Ibarz J (2013) The one-two punch: combination treatment in chronic myeloid leukemia. Crit Rev Oncol Hematol. doi: 10.1016\/j.critrevonc.2013.07.017","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"1226_CR26","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/leu.2011.325","volume":"26","author":"E Traer","year":"2012","unstructured":"Traer E, MacKenzie R, Snead J et al (2012) Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors. Leukemia 26(5):1140\u20131143. doi: 10.1038\/leu.2011.325","journal-title":"Leukemia"},{"issue":"2","key":"1226_CR27","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1517\/14728222.7.2.215","volume":"7","author":"P Traxler","year":"2003","unstructured":"Traxler P (2003) Tyrosine kinases as targets in cancer therapy\u2014successes and failures. Expert Opin Ther Targets 7(2):215\u2013234. doi: 10.1517\/14728222.7.2.215","journal-title":"Expert Opin Ther Targets"},{"key":"1226_CR28","author":"H Wang","year":"2013","unstructured":"Wang H, Zhao L, Zhu LT et al (2013) Wogonin reverses hypoxia resistance of human colon cancer HCT116 cells via downregulation of HIF-1alpha and glycolysis, by inhibiting PI3\u00a0K\/Akt signaling pathway. Mol Carcinog. doi: 10.1002\/mc.22052","journal-title":"Mol Carcinog"},{"issue":"5","key":"1226_CR29","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1158\/1535-7163.MCT-07-2331","volume":"7","author":"E Weisberg","year":"2008","unstructured":"Weisberg E, Wright RD, McMillin DW et al (2008) Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells. Mol Cancer Ther 7(5):1121\u20131129. doi: 10.1158\/1535-7163.MCT-07-2331","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"1226_CR30","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/mc.20789","volume":"51","author":"HY Yang","year":"2012","unstructured":"Yang HY, Zhao L, Yang Z et al (2012) Oroxylin A reverses multi-drug resistance of human hepatoma BEL7402\/5-FU cells via downregulation of P-glycoprotein expression by inhibiting NF-kappaB signaling pathway. Mol Carcinog 51(2):185\u2013195. doi: 10.1002\/mc.20789","journal-title":"Mol Carcinog"},{"issue":"6","key":"1226_CR31","doi-asserted-by":"crossref","first-page":"e20965","DOI":"10.1371\/journal.pone.0020965","volume":"6","author":"X Zhang","year":"2011","unstructured":"Zhang X, Xiao W, Wang L, Tian Z, Zhang J (2011) Deactivation of signal transducer and activator of transcription 3 reverses chemotherapeutics resistance of leukemia cells via down-regulating P-gp. PLoS ONE 6(6):e20965. doi: 10.1371\/journal.pone.0020965","journal-title":"PLoS ONE"},{"key":"1226_CR32","author":"Y Zhang","year":"2013","unstructured":"Zhang Y, Zhao L, Li X et al (2013) V8, a newly synthetic flavonoid, induces apoptosis through ROS-mediated ER stress pathway in hepatocellular carcinoma. Arch Toxicol. doi: 10.1007\/s00204-013-1085-6","journal-title":"Arch Toxicol"},{"issue":"3","key":"1226_CR33","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00280-009-1053-2","volume":"65","author":"L Zhao","year":"2010","unstructured":"Zhao L, Chen Z, Wang J et al (2010) Synergistic effect of 5-fluorouracil and the flavonoid oroxylin A on HepG2 human hepatocellular carcinoma and on H22 transplanted mice. Cancer Chemother Pharmacol 65(3):481\u2013489. doi: 10.1007\/s00280-009-1053-2","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"1226_CR34","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.taap.2012.01.019","volume":"259","author":"B Zhu","year":"2012","unstructured":"Zhu B, Zhao L, Zhu L et al (2012) Oroxylin A reverses CAM-DR of HepG2 cells by suppressing Integrinbeta1 and its related pathway. Toxicol Appl Pharmacol 259(3):387\u2013394. doi: 10.1016\/j.taap.2012.01.019","journal-title":"Toxicol Appl Pharmacol"},{"issue":"2","key":"1226_CR35","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.toxlet.2013.01.019","volume":"219","author":"L Zhu","year":"2013","unstructured":"Zhu L, Zhao L, Wang H et al (2013) Oroxylin A reverses P-glycoprotein-mediated multidrug resistance of MCF7\/ADR cells by G2\/M arrest. Toxicol Lett 219(2):107\u2013115. doi: 10.1016\/j.toxlet.2013.01.019","journal-title":"Toxicol Lett"}],"container-title":["Archives of Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-014-1226-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00204-014-1226-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-014-1226-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,16]],"date-time":"2020-08-16T16:59:03Z","timestamp":1597597143000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00204-014-1226-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,27]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["1226"],"URL":"https:\/\/doi.org\/10.1007\/s00204-014-1226-6","relation":{},"ISSN":["0340-5761","1432-0738"],"issn-type":[{"value":"0340-5761","type":"print"},{"value":"1432-0738","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,27]]}}}